INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29301, 18630, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29302, 25942, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29303, 25943, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29304, 29193, 'Tretinoin (topical)', 'Eczema', 'Topical retinoids may cause severe irritation on eczematous skin.  Therapy with topical retinoids should be avoided on abraded or eczematous skin.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29305, 74, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29306, 81, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29307, 82, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29308, 90, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29309, 91, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29310, 12248, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29311, 13352, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29312, 15595, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29313, 18629, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29314, 18630, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29315, 25942, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29316, 25943, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29317, 29193, 'Tretinoin (topical)', 'Sunburn', 'Retinoid-like products can cause extreme irritation when applied to sunburned skin.  Patients with sunburn should be cautioned not to use retinoid-like acne products until fully recovered, and to avoid prolonged exposure to sunlight (including sunlamps) and use sunscreen/protective clothing during treatment with these products.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29318, 4373, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29319, 4998, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29320, 20406, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29321, 20407, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29322, 20408, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29323, 20432, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29324, 20433, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29325, 31018, 'Trastuzumab emtansine', 'Liver Diseases', 'Serious hepatotoxicity, predominantly in the form of asymptomatic, transient increases in the concentrations of serum transaminases including liver failure and death has been reported in patients treated with the antibody-drug conjugate, ado-trastuzumab emtansine (Kadcyla).  Cases of nodular regenerative hyperplasia (NRH) of the liver, a rare condition characterized by widespread benign transformation of hepatic parenchyma into small regenerative nodules, have been reported in clinical trials.  If NRH is confirmed, treatment must be permanently discontinued.  Monitor serum transaminases and bilirubin before initiation of treatment and before each dose.  It is recommended to reduce the dose or discontinue therapy with ado-trastuzumab emtansine as appropriate in cases of increased serum transaminases or total bilirubin.  In patients with serum transaminases > 3 × ULN and concomitant total bilirubin > 2 × ULN, permanently discontinue treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29326, 4373, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29327, 4998, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29328, 20406, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29329, 20407, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29330, 20408, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29331, 20432, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29332, 20433, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29333, 31018, 'Trastuzumab emtansine', 'Lung Diseases', 'Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity.  Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis.  Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity.  Patients should be monitored for pulmonary symptoms.  Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29334, 4373, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29335, 4998, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29336, 20406, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29337, 20407, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29338, 20408, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29339, 20432, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29340, 20433, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29341, 31018, 'Trastuzumab emtansine', 'Heart Failure', 'Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity.  Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF.  Therapy with these agents should be administered cautiously in patients with a previous history of heart conditions.  Evaluate cardiac function before, during, and upon completion of treatment.  Withhold or discontinue therapy with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further.  It is recommended to monitor overall cardiac function and LVEF by echocardiogram or MUGA scan as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29342, 4373, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29343, 4998, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29344, 20406, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29345, 20407, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29346, 20408, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29347, 20432, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29348, 20433, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29349, 31018, 'Trastuzumab emtansine', 'Peripheral Nervous System Diseases', 'Peripheral neuropathy has been reported with the use of agents that block HER2 activity.  Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents.  Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution.  Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29350, 4373, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29351, 4998, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29352, 20406, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29353, 20407, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29354, 20408, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29355, 20432, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29356, 20433, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29357, 31018, 'Trastuzumab emtansine', 'Thrombocytopenia', 'Thrombocytopenia has been reported with the use of agents that block HER2 activity.  Monitor platelet counts prior to initiation of therapy and prior to each dose.  If appropriate modify the dose according to clinical guidelines.  Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29358, 74, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29359, 81, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29360, 82, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29361, 90, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29362, 91, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29363, 12248, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29364, 13352, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29365, 15595, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29366, 18629, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29367, 18630, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29368, 25942, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29369, 25943, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29370, 29193, 'Tretinoin', 'Liver Diseases', 'Elevated liver enzymes have been reported in 50% to 60% of patients administered tretinoin.  These abnormalities are usually reversible, however, patients with hepatic impairment may be at increased risk of hepatotoxicity associated with tretinoin.  Clinical monitoring of hepatic function is necessary and consideration should be given to withholding tretinoin therapy if enzyme levels reach 5 times the upper limit of normal values.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29371, 74, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29372, 81, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29373, 82, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29374, 90, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29375, 91, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29376, 12248, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29377, 13352, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29378, 15595, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29379, 18629, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29380, 18630, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29381, 25942, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29382, 25943, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29383, 29193, 'Tretinoin', 'Hyperlipidemias', 'A reversible elevation of cholesterol and/or triglycerides has been reported in up to 60% of patients administered tretinoin.  Venous thrombosis and myocardial infarction have occurred in patients at low risk for such complications.  Therapy with tretinoin should be administered cautiously in patients with or predisposed to hypercholesterolemia and/or hypertriglyceridemia.  Clinical monitoring of lipid profile is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29384, 6838, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29385, 6840, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29386, 11634, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29387, 23270, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29388, 28461, 'Triamcinolone', 'Infections', 'The immunosuppressant and anti-inflammatory effects of corticosteroids, particularly in higher dosages, may decrease host resistance to infectious agents, decrease the ability to localize infections, and mask the symptoms of infection.  Secondary infections may be more likely to develop.  In general, corticosteroids should not be used in patients with active infections, especially systemic fungal infections, unless they are medically necessary and effective antimicrobial therapy or other appropriate treatment has been instituted.  However, for corticosteroid-dependent patients who develop a severe or life-threatening infection, continuation of corticosteroid therapy with at least physiologic replacement dosages should be considered, since these patients may have secondary adrenocortical insufficiency.  Removal of external steroid during periods of stress may be detrimental to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29389, 6838, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29390, 6840, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29391, 11634, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29392, 23270, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29393, 28461, 'Triamcinolone', 'Premature Birth', 'The use of certain parenteral formulations of dexamethasone, hydrocortisone, methylprednisolone, prednisolone and triamcinolone is considered by the drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  Some formulations of these drugs contain benzyl alcohol which, when used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  Continuous infusions of high dosages of medications containing benzyl alcohol may, however, cause toxicity and should be avoided if possible.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29394, 6838, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29395, 6840, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29396, 11634, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29397, 23270, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29398, 28461, 'Triamcinolone', 'Latent Tuberculosis', 'In patients with latent tuberculosis or tuberculin reactivity, the use of pharmacologic dosages of corticosteroids may cause a reactivation of the disease.  Close monitoring for signs and symptoms of tuberculosis is recommended if corticosteroid therapy is administered to patients with a history of tuberculosis or tuberculin reactivity.  During prolonged corticosteroid therapy, tuberculosis chemoprophylaxis may be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29399, 6838, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29400, 6840, 'Triamcinolone', 'Fibrosis', 'Corticosteroids may have enhanced effects on patients with cirrhosis due to decreased metabolism of these agents.  Patients with cirrhosis should be monitored more closely for excessive cortisol effects.  Dosage adjustments may be required in these patients.', '2', '', 'DDInter', 0);
